Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

This issue highlights a broader concern regarding medication coverage and affordable health care. It underscores the critical ...

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S.

However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

The drug for which spending increased the most due to a price increase was Gilead’s HIV treatment Biktarvy. The company ...

Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...

The Maine Bureau of Insurance announced Monday that the carrier reversed its initial decision and will cover eight HIV ...

U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the ...